id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-1977-N-0018-0101,FDA,FDA-1977-N-0018,"Citizen Petition Denial Response from FDA to Bayer Healthcare, LLC",Other,Denial,2014-05-02T04:00:00Z,2014,5,2014-05-02T04:00:00Z,,2014-05-02T21:22:30Z,,0,0,09000064816def57
FDA-1977-N-0018-0097,FDA,FDA-1977-N-0018,"Tab Attachment re: Supplement from Bayer Healthcare, LLC",Supporting & Related Material,Background Material,2014-05-02T04:00:00Z,2014,5,,,2019-02-05T16:24:08Z,,0,0,09000064805d9b8b
FDA-1977-N-0018-0093,FDA,FDA-1977-N-0018,"Supplement from Bayer HealthCare LLC, Consumer Care Division",Other,Supplement (SUP),2014-05-02T04:00:00Z,2014,5,2014-05-02T04:00:00Z,,2019-02-01T14:49:41Z,,0,0,09000064805d99b0
FDA-1977-N-0018-0100,FDA,FDA-1977-N-0018,"Memorandum of Meeting Between FDA/CDER and Bayer HealthCare dated April 30, 2014",Other,Memorandum,2014-05-02T04:00:00Z,2014,5,2014-05-02T04:00:00Z,,2019-01-29T17:24:51Z,,0,0,09000064805d99c0
FDA-1977-N-0018-0095,FDA,FDA-1977-N-0018,"Supplement from Innovative Science Solutions, LLC",Other,Supplement (SUP),2014-05-02T04:00:00Z,2014,5,2014-05-02T04:00:00Z,,2019-02-05T17:39:06Z,,0,0,09000064805d9b88
FDA-1977-N-0018-0094,FDA,FDA-1977-N-0018,Supplement from Clinical Trial Service Unit & Epidemiological Studies Unit-University of Oxford,Other,Supplement (SUP),2014-05-02T04:00:00Z,2014,5,,,2019-02-05T15:35:43Z,,0,0,09000064805d9b80
FDA-1977-N-0018-0092,FDA,FDA-1977-N-0018,"Citizen Petition from Bayer Healthcare, LLC",Other,Citizen Petition,2014-05-02T04:00:00Z,2014,5,2014-05-02T04:00:00Z,,2019-02-05T18:40:00Z,,0,0,09000064805d9995
FDA-1977-N-0018-0098,FDA,FDA-1977-N-0018,Supplement from University of Alabama at Birmingham (UAB),Other,Supplement (SUP),2014-05-02T04:00:00Z,2014,5,2014-05-02T04:00:00Z,,2019-02-05T16:28:32Z,,0,0,09000064805d9b8d
FDA-1977-N-0018-0096,FDA,FDA-1977-N-0018,"Supplement from Bayer Healthcare, LLC",Other,Supplement (SUP),2014-05-02T04:00:00Z,2014,5,2014-05-02T04:00:00Z,,2019-02-05T16:23:38Z,,0,0,09000064805d9b8a
FDA-1977-N-0018-0091,FDA,FDA-1977-N-0018,Drug Products for the Treatment and/or Prevention of Nocturnal Leg Muscle Cramps for Over-the-Counter Human Use; Final Rule,Notice,Notice of Final Rule,2012-12-19T05:00:00Z,2012,12,2012-12-19T05:00:00Z,,2018-12-26T13:27:13Z,94-20449,0,0,09000064805d9854
FDA-1977-N-0018-0090,FDA,FDA-1977-N-0018,"Letter from Akin, Gump, Strauss, Hauer & Feld, L.L.P on behalf of PharmaControl Corporation (Pharmaceuticals Formulations Incorporated) to FDA CDER",Other,Letter(s),2012-12-19T05:00:00Z,2012,12,,,2019-02-27T21:39:51Z,,0,0,09000064805d9842
FDA-1977-N-0018-0084,FDA,FDA-1977-N-0018,Joint Meeting of The Nonprecription Drug Advisory Committee and the Cardiovascular and Renal Drugs Advisory Committee - Transcript,Other,Transcript(s),2011-02-16T05:00:00Z,2011,2,2011-02-16T05:00:00Z,,2012-12-07T15:17:56Z,,0,0,0900006480bf023e
FDA-1977-N-0018-0079,FDA,FDA-1977-N-0018,Acknowledgment Letter from FDA/DDM to Dr. Brian Kaplan,Other,Acknowledgement Letter/Receipt,2007-05-29T04:00:00Z,2007,5,,,2019-02-05T17:23:36Z,,0,0,09000064805d9b9a
FDA-1977-N-0018-0078,FDA,FDA-1977-N-0018,"Letter from FDA/CDER to Innovative Science Solutions, LLC",Other,Letter(s),2005-05-17T04:00:00Z,2005,5,,,2019-02-05T16:10:31Z,,0,0,09000064805d9b86
FDA-1977-N-0018-0062,FDA,FDA-1977-N-0018,Answer from FDA to Letter from Mallard Inc.,Other,Answer,2004-08-10T04:00:00Z,2004,8,,,2018-12-21T14:13:12Z,,0,0,09000064805d99c7
FDA-1977-N-0018-0056,FDA,FDA-1977-N-0018,FDA/CDER,Other,M-Memorandum,2004-04-28T04:00:00Z,2004,4,,,2010-04-08T15:52:21Z,,0,0,09000064805d99bf
FDA-1977-N-0018-0055,FDA,FDA-1977-N-0018,Memorandum between FDA and Bayer Health Care LLC,Other,Memorandum,2004-04-28T04:00:00Z,2004,4,,,2019-01-29T17:22:10Z,,0,0,09000064805d99be
FDA-1977-N-0018-0054,FDA,FDA-1977-N-0018,"Memorandum of Meeting Between FDA/CDER and Bayer HealthCare dated November 19, 2003",Other,Memorandum,2003-12-09T05:00:00Z,2003,12,,,2019-02-04T17:13:11Z,,0,0,09000064805d99ab
FDA-1977-N-0018-0053,FDA,FDA-1977-N-0018,"Memorandum between Representatives of FDA and Bayer HealthCare, LLC",Other,Memorandum,2003-11-12T05:00:00Z,2003,11,,,2019-02-04T17:15:11Z,,0,0,09000064805d99aa
FDA-1977-N-0018-0052,FDA,FDA-1977-N-0018,Internal Memorandum from Charles J Ganley (HFD-560) to FDA/DDM (HFA-305) August 8 2003,Other,Memorandum,2003-08-22T04:00:00Z,2003,8,,,2019-02-01T14:33:27Z,,0,0,09000064805d99a3
FDA-1977-N-0018-0051,FDA,FDA-1977-N-0018,"Letter from FDA/CDER to Bayer HealthCare, LLC",Other,Letter(s),2003-08-22T04:00:00Z,2003,8,,,2019-01-28T21:43:10Z,,0,0,09000064805d99a2
FDA-1977-N-0018-0080,FDA,FDA-1977-N-0018,Acknowledgment Letter from FDA DDM re: Citizen Petition from Whitehall-Robins Healthcare (A Division of American Home Products Corporation) (Volume 1 of 4),Other,Acknowledgement Letter/Receipt,1997-11-28T05:00:00Z,1997,11,,,2019-02-05T13:16:24Z,,0,0,09000064805d9b9d